GPS, PLAT, and Transmembrane Domain-Containing Protein (LOC399491): A Potential Drug Target and Biomarker

Target Name: GPS, PLAT and transmembrane domain-containing protein

NCBI ID: G399491

GPS, PLAT and transmembrane domain-containing protein

Other Name(s): LOC399491

GPS, PLAT, and Transmembrane Domain-Containing Protein (LOC399491): A Potential Drug Target and Biomarker

Gastrointestinal (GI) cancers, including colon cancer, are a leading cause of cancer-related deaths worldwide. Despite advances in cancer treatment, the survival rate for advanced stages of GI cancer remains high. Therefore, there is a need for new therapeutic approaches that can effectively target these diseases.

One potential approach to combatting GI cancer is the targeting of PLAT, a transmembrane protein that is expressed in various tissues and has been implicated in cancer progression. PLAT has been shown to promote the growth and survival of various types of cancer cells, including GI malignancies.

Furthermore, LOC399491, a gene encoding a protein that is highly similar to PLAT, has also been shown to be involved in cancer development. The LOC399491 gene has been identified as a potential drug target and biomarker for GI cancer.

The LOC399491 gene encodes a transmembrane protein that is composed of a cytoplasmic region, a transmembrane region, and an extracellular region. The cytoplasmic region contains a single protein that is similar to PLAT, while the transmembrane region contains a unique protein that is not known to be similar to PLAT. The extracellular region contains various domains, including a N-terminal domain, a C-terminal domain, and a carboxy-terminal domain.

Expression of LOC399491 has been shown to be involved in various processes that are related to cancer development, including cell growth, survival, and angiogenesis. For example, LOC399491 has been shown to promote the growth and survival of various types of cancer cells, including colon cancer.

Furthermore, LOC399491 has been shown to be involved in the regulation of cell adhesion. This is important because adhesion is a critical process that helps cells stick together and form tissues. The regulation of cell adhesion is also important for cancer progression, as changes in cell adhesion can contribute to tumor growth and the development of invasive tumors.

In addition to its role in cell adhesion, LOC399491 has also been shown to be involved in the regulation of cell signaling pathways. This is important because signaling pathways are critical for cell growth, survival, and angiogenesis. The regulation of cell signaling pathways is also important for cancer progression, as changes in signaling pathways can contribute to tumor growth and the development of invasive tumors.

The potential drug target for LOC399491 is the inhibition of its activity, either by targeting its protein or by inhibiting its signaling pathway. This could be done using small molecules, such as drugs that bind to LOC399491, or by using antibodies that specifically target LOC399491.

In addition to its potential as a drug target, LOC399491 has also been identified as a potential biomarker for GI cancer. This is because its expression has been shown to be involved in the development and progression of various types of cancer. For example, LOC399491 has been shown to be involved in the development of colon cancer.

The development of new diagnostic tests and therapeutic approaches is an important step in the fight against cancer. The potential of LOC399491 as a drug target and biomarker for GI cancer makes it an attractive target for further research. Further studies are needed to understand the full role of LOC399491 in cancer development and to develop new diagnostic tests and therapeutic approaches that can effectively target this disease.

Protein Name: GPS, PLAT And Transmembrane Domain-containing Protein

The "GPS, PLAT and transmembrane domain-containing protein Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPS, PLAT and transmembrane domain-containing protein comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets